Get the Stockscreener App
6.48
0.93%
+0.06
After Hours:
7.00
0.52
+8.02%
Lantern Pharma Inc stock is currently priced at $6.48, with a 24-hour trading volume of 56,456.
It has seen a +0.93% increased in the last 24 hours and a -16.82% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $6.56 pivot point. If it approaches the $6.09 support level, significant changes may occur.
Previous Close:
$6.42
Open:
$6.52
24h Volume:
56,456
Market Cap:
$69.72M
Revenue:
-
Net Income/Loss:
$-15.16M
P/E Ratio:
-4.9039
EPS:
-1.3214
Net Cash Flow:
$-13.65M
1W Performance:
+20.22%
1M Performance:
-16.82%
6M Performance:
+131.43%
1Y Performance:
+22.26%
1D Range:
$6.20
$6.82
52W Range:
$2.38
$11.99
Lantern Pharma Inc Stock (LTRN) Company Profile
Name
Lantern Pharma Inc
Sector
Industry
Phone
972 277 1136
Address
1920 McKinney Avenue, 7th Floor, Dallas, TX
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-21 | Initiated | H.C. Wainwright | Buy |
Lantern Pharma Inc Stock (LTRN) Latest News
Lantern Pharma Inc Stock (LTRN) Financials Data
Lantern Pharma Inc (LTRN) Net Income 2024
LTRN net income (TTM) was -$15.16 million for the quarter ending September 30, 2023, a -5.12% decrease year-over-year.
Lantern Pharma Inc (LTRN) Cash Flow 2024
LTRN recorded a free cash flow (TTM) of -$13.65 million for the quarter ending September 30, 2023, a -12.27% decrease year-over-year.
Lantern Pharma Inc (LTRN) Earnings per Share 2024
LTRN earnings per share (TTM) was -$1.40 for the quarter ending September 30, 2023, a -6.12% decline year-over-year.
Lantern Pharma Inc Stock (LTRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fletcher Aaron G.L. | 10% Owner |
Feb 29 '24 |
Sale |
4.87 |
19,703 |
95,954 |
60,256 |
| Fletcher Aaron G.L. | 10% Owner |
Feb 28 '24 |
Sale |
4.85 |
74,297 |
360,340 |
62,088 |
| Kreis Leslie W. | 10% Owner |
Feb 28 '24 |
Sale |
4.85 |
74,297 |
360,340 |
62,088 |
| Kreis Leslie W. | 10% Owner |
Feb 27 '24 |
Sale |
4.40 |
50,000 |
220,000 |
68,997 |
| Fletcher Aaron G.L. | 10% Owner |
Feb 27 '24 |
Sale |
4.40 |
50,000 |
220,000 |
68,997 |
| Kreis Leslie W. | 10% Owner |
Jan 17 '24 |
Sale |
4.20 |
58,889 |
247,334 |
73,646 |
| Fletcher Aaron G.L. | 10% Owner |
Jan 17 '24 |
Sale |
4.20 |
58,889 |
247,334 |
73,646 |
| Kreis Leslie W. | 10% Owner |
Nov 29 '23 |
Sale |
3.44 |
145,348 |
499,997 |
217,553 |
| Fletcher Aaron G.L. | 10% Owner |
Nov 29 '23 |
Sale |
3.44 |
145,348 |
499,997 |
217,553 |
About Lantern Pharma Inc
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
0.91%
2.42%
Cap:
|
Volume (24h):